Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania

<p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to s...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Berens-Riha Nicole [verfasserIn] Maboko Leonard [verfasserIn] Hoelscher Michael [verfasserIn] Maduhu Ibrahim [verfasserIn] Schunk Mirjam [verfasserIn] Barreto Miranda Isabel [verfasserIn] Schönfeld Mirjam [verfasserIn] Kitua Andrew [verfasserIn] Löscher Thomas [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2007

Übergeordnetes Werk:	In: Malaria Journal - BMC, 2003, 6(2007), 1, p 2
Übergeordnetes Werk:	volume:6 ; year:2007 ; number:1, p 2

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1186/1475-2875-6-2

Katalog-ID:	DOAJ037123122

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ037123122
003	DE-627
005	20230308000407.0
007	cr uuu---uuuuu
008	230227s2007 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/1475-2875-6-2 \|2 doi
035			\|a (DE-627)DOAJ037123122
035			\|a (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC955-962
050		0	\|a RC109-216
100	0		\|a Berens-Riha Nicole \|e verfasserin \|4 aut
245	1	0	\|a Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania
264		1	\|c 2007
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p<
653		0	\|a Arctic medicine. Tropical medicine
653		0	\|a Infectious and parasitic diseases
700	0		\|a Maboko Leonard \|e verfasserin \|4 aut
700	0		\|a Hoelscher Michael \|e verfasserin \|4 aut
700	0		\|a Maduhu Ibrahim \|e verfasserin \|4 aut
700	0		\|a Schunk Mirjam \|e verfasserin \|4 aut
700	0		\|a Barreto Miranda Isabel \|e verfasserin \|4 aut
700	0		\|a Schönfeld Mirjam \|e verfasserin \|4 aut
700	0		\|a Kitua Andrew \|e verfasserin \|4 aut
700	0		\|a Löscher Thomas \|e verfasserin \|4 aut
773	0	8	\|i In \|t Malaria Journal \|d BMC, 2003 \|g 6(2007), 1, p 2 \|w (DE-627)355986582 \|w (DE-600)2091229-8 \|x 14752875 \|7 nnns
773	1	8	\|g volume:6 \|g year:2007 \|g number:1, p 2
856	4	0	\|u https://doi.org/10.1186/1475-2875-6-2 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 \|z kostenfrei
856	4	0	\|u http://www.malariajournal.com/content/6/1/2 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1475-2875 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 6 \|j 2007 \|e 1, p 2

Indexfelder

author_variant	b r n brn m l ml h m hm m i mi s m sm b m i bmi s m sm k a ka l t lt
matchkey_str	article:14752875:2007----::oeuasrelacodurssacascaemttosftlsoimac
hierarchy_sort_str	2007
callnumber-subject-code	RC
publishDate	2007
allfields	10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2
spelling	10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2
allfields_unstemmed	10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2
allfieldsGer	10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2
allfieldsSound	10.1186/1475-2875-6-2 doi (DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7 DE-627 ger DE-627 rakwb eng RC955-962 RC109-216 Berens-Riha Nicole verfasserin aut Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p< Arctic medicine. Tropical medicine Infectious and parasitic diseases Maboko Leonard verfasserin aut Hoelscher Michael verfasserin aut Maduhu Ibrahim verfasserin aut Schunk Mirjam verfasserin aut Barreto Miranda Isabel verfasserin aut Schönfeld Mirjam verfasserin aut Kitua Andrew verfasserin aut Löscher Thomas verfasserin aut In Malaria Journal BMC, 2003 6(2007), 1, p 2 (DE-627)355986582 (DE-600)2091229-8 14752875 nnns volume:6 year:2007 number:1, p 2 https://doi.org/10.1186/1475-2875-6-2 kostenfrei https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 kostenfrei http://www.malariajournal.com/content/6/1/2 kostenfrei https://doaj.org/toc/1475-2875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2007 1, p 2
language	English
source	In Malaria Journal 6(2007), 1, p 2 volume:6 year:2007 number:1, p 2
sourceStr	In Malaria Journal 6(2007), 1, p 2 volume:6 year:2007 number:1, p 2
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Arctic medicine. Tropical medicine Infectious and parasitic diseases
isfreeaccess_bool	true
container_title	Malaria Journal
authorswithroles_txt_mv	Berens-Riha Nicole @@aut@@ Maboko Leonard @@aut@@ Hoelscher Michael @@aut@@ Maduhu Ibrahim @@aut@@ Schunk Mirjam @@aut@@ Barreto Miranda Isabel @@aut@@ Schönfeld Mirjam @@aut@@ Kitua Andrew @@aut@@ Löscher Thomas @@aut@@
publishDateDaySort_date	2007-01-01T00:00:00Z
hierarchy_top_id	355986582
id	DOAJ037123122
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ037123122</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308000407.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2007 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1475-2875-6-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ037123122</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC955-962</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Berens-Riha Nicole</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Arctic medicine. Tropical medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maboko Leonard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoelscher Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maduhu Ibrahim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schunk Mirjam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barreto Miranda Isabel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schönfeld Mirjam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kitua Andrew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Löscher Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Malaria Journal</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">6(2007), 1, p 2</subfield><subfield code="w">(DE-627)355986582</subfield><subfield code="w">(DE-600)2091229-8</subfield><subfield code="x">14752875</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:1, p 2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1475-2875-6-2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.malariajournal.com/content/6/1/2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1475-2875</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2007</subfield><subfield code="e">1, p 2</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Berens-Riha Nicole
spellingShingle	Berens-Riha Nicole misc RC955-962 misc RC109-216 misc Arctic medicine. Tropical medicine misc Infectious and parasitic diseases Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania
authorStr	Berens-Riha Nicole
ppnlink_with_tag_str_mv	@@773@@(DE-627)355986582
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC955-962
illustrated	Not Illustrated
issn	14752875
topic_title	RC955-962 RC109-216 Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania
topic	misc RC955-962 misc RC109-216 misc Arctic medicine. Tropical medicine misc Infectious and parasitic diseases
topic_unstemmed	misc RC955-962 misc RC109-216 misc Arctic medicine. Tropical medicine misc Infectious and parasitic diseases
topic_browse	misc RC955-962 misc RC109-216 misc Arctic medicine. Tropical medicine misc Infectious and parasitic diseases
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Malaria Journal
hierarchy_parent_id	355986582
hierarchy_top_title	Malaria Journal
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)355986582 (DE-600)2091229-8
title	Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania
ctrlnum	(DE-627)DOAJ037123122 (DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7
title_full	Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania
author_sort	Berens-Riha Nicole
journal	Malaria Journal
journalStr	Malaria Journal
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2007
contenttype_str_mv	txt
author_browse	Berens-Riha Nicole Maboko Leonard Hoelscher Michael Maduhu Ibrahim Schunk Mirjam Barreto Miranda Isabel Schönfeld Mirjam Kitua Andrew Löscher Thomas
container_volume	6
class	RC955-962 RC109-216
format_se	Elektronische Aufsätze
author-letter	Berens-Riha Nicole
doi_str_mv	10.1186/1475-2875-6-2
author2-role	verfasserin
title_sort	molecular surveillance of drug-resistance associated mutations of <it<plasmodium falciparum </it<in south-west tanzania
callnumber	RC955-962
title_auth	Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania
abstract	<p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p<
abstractGer	<p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p<
abstract_unstemmed	<p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p<
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1, p 2
title_short	Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania
url	https://doi.org/10.1186/1475-2875-6-2 https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7 http://www.malariajournal.com/content/6/1/2 https://doaj.org/toc/1475-2875
remote_bool	true
author2	Maboko Leonard Hoelscher Michael Maduhu Ibrahim Schunk Mirjam Barreto Miranda Isabel Schönfeld Mirjam Kitua Andrew Löscher Thomas
author2Str	Maboko Leonard Hoelscher Michael Maduhu Ibrahim Schunk Mirjam Barreto Miranda Isabel Schönfeld Mirjam Kitua Andrew Löscher Thomas
ppnlink	355986582
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/1475-2875-6-2
callnumber-a	RC955-962
up_date	2024-07-04T00:00:48.438Z
_version_	1803604457899950080
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ037123122</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308000407.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2007 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1475-2875-6-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ037123122</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5bd9e38fa5a74d438eeab7459881e0f7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC955-962</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Berens-Riha Nicole</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (<it<pfdhfr</it<) and dihydropteroate synthase (<it<pfdhps</it<) genes.</p< <p<Methods</p< <p<In samples from 86 patients with uncomplicated <it<Plasmodium falciparum </it<malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the <it<pfcrt </it<and <it<pfmdr1 </it<genes which are associated with CQ resistance and in <it<pfdhfr </it<and <it<pfdhps</it<, conferring SP resistance, as well in <it<cytb </it<which is linked to resistance to atovaquone.</p< <p<Results</p< <p<<it<Pfcrt </it<T76 occurs in 50% and <it<pfmdr1 </it<Y86 in 51.7%. <it<Pfdhfr </it<triple mutations coexisting with <it<pfdhps </it<double mutations were detected in 64.3% of the <it<P. falciparum </it<isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the <it<cytb </it<gene were not detected.</p< <p<Conclusion</p< <p<These findings of a high prevalence of mutations conferring SP resistance correspond to data of <it<in vivo </it<SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Arctic medicine. Tropical medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maboko Leonard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoelscher Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maduhu Ibrahim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schunk Mirjam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barreto Miranda Isabel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Schönfeld Mirjam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kitua Andrew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Löscher Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Malaria Journal</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">6(2007), 1, p 2</subfield><subfield code="w">(DE-627)355986582</subfield><subfield code="w">(DE-600)2091229-8</subfield><subfield code="x">14752875</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:1, p 2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1475-2875-6-2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5bd9e38fa5a74d438eeab7459881e0f7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.malariajournal.com/content/6/1/2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1475-2875</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2007</subfield><subfield code="e">1, p 2</subfield></datafield></record></collection>
score	7.4004774

Nicht das Richtige dabei?

Schreiben Sie uns!

Molecular surveillance of drug-resistance associated mutations of <it<Plasmodium falciparum </it<in south-west Tanzania

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?